Artios raises $115M Series D to accelerate first-in-class cancer therapies
Artios raises $115M Series D to accelerate first-in-class cancer therapies Biotech company Artios today announced the successful close of an oversubscribed $115 million Series D financing. Artios is pioneering next-generation approaches in the DNA damage response (DDR) field through its comprehensive anti-cancer approach and the deep experience of its team

